GB0720038D0 - New compounds - Google Patents
New compoundsInfo
- Publication number
- GB0720038D0 GB0720038D0 GBGB0720038.9A GB0720038A GB0720038D0 GB 0720038 D0 GB0720038 D0 GB 0720038D0 GB 0720038 A GB0720038 A GB 0720038A GB 0720038 D0 GB0720038 D0 GB 0720038D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- new compounds
- compounds
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0720038.9A GB0720038D0 (en) | 2007-10-12 | 2007-10-12 | New compounds |
SI200831645A SI2203449T1 (sl) | 2007-10-12 | 2008-10-10 | Biciklične heterociklične spojine kot inhibitorji protein tirozi kinaze |
PT88065750T PT2203449T (pt) | 2007-10-12 | 2008-10-10 | Compostos heterocíclicos bicíclicos como inibidores da proteína tirosina cinase |
EP08806575.0A EP2203449B1 (en) | 2007-10-12 | 2008-10-10 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
CA2701868A CA2701868C (en) | 2007-10-12 | 2008-10-10 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
PCT/GB2008/003439 WO2009047522A1 (en) | 2007-10-12 | 2008-10-10 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
JP2010528481A JP5562858B2 (ja) | 2007-10-12 | 2008-10-10 | タンパク質チロシンキナーゼインヒビターとしての二環式ヘテロ環式化合物 |
HUE08806575A HUE028999T2 (en) | 2007-10-12 | 2008-10-10 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
PL08806575T PL2203449T3 (pl) | 2007-10-12 | 2008-10-10 | Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej |
AU2008309342A AU2008309342C1 (en) | 2007-10-12 | 2008-10-10 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
US12/682,478 US8071614B2 (en) | 2007-10-12 | 2008-10-10 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
RS20160587A RS55045B1 (sr) | 2007-10-12 | 2008-10-10 | Biciklična heterociklična jedinjenja kao inhibitori tirozin kinaze proteina |
ES08806575.0T ES2585352T3 (es) | 2007-10-12 | 2008-10-10 | Compuestos bicíclicos heterocíclicos como inhibidores de la proteína tirosina quinasa |
MEP-2016-141A ME02815B (me) | 2007-10-12 | 2008-10-10 | Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze |
HK10111956.7A HK1145496A1 (zh) | 2007-10-12 | 2010-12-21 | 作為蛋白酪氨酸激酶抑制劑的雙環雜環化合物 |
US13/275,752 US8859582B2 (en) | 2007-10-12 | 2011-10-18 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
HRP20160852TT HRP20160852T1 (hr) | 2007-10-12 | 2016-07-13 | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze |
CY20161100727T CY1117820T1 (el) | 2007-10-12 | 2016-07-25 | Δικυκλικες ετερο-κυκλικες ενωσεις σαν καταστολεις κινασης (kinase) πρωτεϊνης |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0720038.9A GB0720038D0 (en) | 2007-10-12 | 2007-10-12 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0720038D0 true GB0720038D0 (en) | 2007-11-21 |
Family
ID=38788130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0720038.9A Ceased GB0720038D0 (en) | 2007-10-12 | 2007-10-12 | New compounds |
Country Status (17)
Country | Link |
---|---|
US (2) | US8071614B2 (el) |
EP (1) | EP2203449B1 (el) |
JP (1) | JP5562858B2 (el) |
AU (1) | AU2008309342C1 (el) |
CA (1) | CA2701868C (el) |
CY (1) | CY1117820T1 (el) |
ES (1) | ES2585352T3 (el) |
GB (1) | GB0720038D0 (el) |
HK (1) | HK1145496A1 (el) |
HR (1) | HRP20160852T1 (el) |
HU (1) | HUE028999T2 (el) |
ME (1) | ME02815B (el) |
PL (1) | PL2203449T3 (el) |
PT (1) | PT2203449T (el) |
RS (1) | RS55045B1 (el) |
SI (1) | SI2203449T1 (el) |
WO (1) | WO2009047522A1 (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
AR064491A1 (es) * | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
CN104884452A (zh) | 2012-11-20 | 2015-09-02 | 沃泰克斯药物股份有限公司 | 用作吲哚胺2,3-二氧化酶的抑制剂的化合物 |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
CA2907243C (en) | 2013-03-15 | 2021-12-28 | Celgene Avilomics Research, Inc. | Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor |
ES2657451T3 (es) | 2013-04-19 | 2018-03-05 | Incyte Holdings Corporation | Heterocíclicos bicíclicos como inhibidores del FGFR |
CN106660997B (zh) | 2014-08-18 | 2019-05-21 | 卫材R&D管理有限公司 | 单环吡啶衍生物的盐及其晶体 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
US10208024B2 (en) | 2015-10-23 | 2019-02-19 | Array Biopharma Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN111225917A (zh) | 2017-10-24 | 2020-06-02 | 拜耳股份公司 | 取代咪唑并吡啶酰胺及其用途 |
MX2020008610A (es) | 2018-03-28 | 2020-09-21 | Eisai R&D Man Co Ltd | Agente terapeutico para carcinoma hepatocelular. |
JP2021523118A (ja) | 2018-05-04 | 2021-09-02 | インサイト・コーポレイションIncyte Corporation | Fgfr阻害剤の塩 |
CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN114072402B (zh) * | 2019-07-26 | 2023-12-26 | 盛世泰科生物医药技术(苏州)股份有限公司 | 作为fgfr和vegfr双重抑制剂的吡啶衍生物 |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤の誘導体 |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
US20230115945A1 (en) | 2019-12-30 | 2023-04-13 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
KR20230152654A (ko) | 2020-12-30 | 2023-11-03 | 타이라 바이오사이언시스, 인크. | 키나아제 억제제로서의 인다졸 화합물 |
KR20230154436A (ko) | 2021-02-26 | 2023-11-08 | 타이라 바이오사이언시스, 인크. | 아미노피리미딘 화합물 및 그의 사용 방법 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2024006883A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
WO2024006897A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
EP0308020A3 (en) | 1987-09-18 | 1990-12-05 | Merck & Co. Inc. | 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5554630A (en) | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
WO1995035296A1 (en) | 1994-06-20 | 1995-12-28 | Takeda Chemical Industries, Ltd. | Condensed imidazole compounds, their production and use |
WO1996034866A1 (en) | 1995-05-01 | 1996-11-07 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors |
WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
ATE375344T1 (de) | 1996-07-24 | 2007-10-15 | Bristol Myers Squibb Pharma Co | Azolotriazine und pyrimidine |
CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
US5990146A (en) * | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6465484B1 (en) * | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
WO2000012089A1 (en) | 1998-08-31 | 2000-03-09 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
NZ505079A (en) | 1998-01-28 | 2003-08-29 | Du Pont Pharm Co | Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists |
US6245759B1 (en) * | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2001000207A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
AU5636900A (en) * | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
US6316444B1 (en) | 1999-06-30 | 2001-11-13 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB9921150D0 (en) | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
GB9927687D0 (en) | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
WO2001064674A1 (en) | 2000-03-01 | 2001-09-07 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
BR0109107A (pt) | 2000-03-09 | 2002-12-03 | Aventis Pharma Gmbh | Usos terapêuticos de mediadores ppar |
US20020041880A1 (en) * | 2000-07-05 | 2002-04-11 | Defeo-Jones Deborah | Method of treating cancer |
WO2002012238A2 (en) | 2000-08-04 | 2002-02-14 | Warner-Lambert Company | 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
AU2001295992A1 (en) | 2000-10-24 | 2002-05-06 | Sankyo Company Limited | Imidazopyridine derivatives |
GB0027561D0 (en) | 2000-11-10 | 2000-12-27 | Merck Sharp & Dohme | Therapeutic agents |
AU2002221239A1 (en) | 2000-12-07 | 2002-06-18 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
US20020107262A1 (en) | 2000-12-08 | 2002-08-08 | 3M Innovative Properties Company | Substituted imidazopyridines |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
MXPA03007266A (es) | 2001-02-20 | 2003-12-04 | Astrazeneca Ab | 2-arilamino-pirimidinas para tratamiento de desordenes relacionados a glucogeno-sintasa cinasa-3(gsk3). |
SE0100567D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
TWI248936B (en) | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
DE10117183A1 (de) | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
WO2002088107A1 (en) * | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
CA2483306A1 (en) * | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
US7125888B2 (en) | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AUPS251402A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Kinase inhibitors |
DE60331187D1 (de) | 2002-05-23 | 2010-03-25 | Cytopia Res Pty Ltd | Kinaseinhibitoren |
GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
GB0212049D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
AU2003240488A1 (en) | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
PA8577501A1 (es) * | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
CN100549011C (zh) | 2002-09-19 | 2009-10-14 | 先灵公司 | 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶 |
GB0223349D0 (en) * | 2002-10-08 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic agents |
AU2003271185A1 (en) | 2002-10-15 | 2004-05-04 | Takeda Pharmaceutical Company Limited | Imidazopyridine derivative, process for producing the same, and use |
WO2004052286A2 (en) | 2002-12-11 | 2004-06-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
US7826979B2 (en) * | 2003-02-14 | 2010-11-02 | Vertex Pharmaceuticals Incorporated | Method of modeling complex formation between a query ligan and a target molecule |
US7476670B2 (en) * | 2003-02-18 | 2009-01-13 | Aventis Pharma S.A. | Purine derivatives, method for preparing, pharmaceutical compositions and novel use |
US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
US7442709B2 (en) | 2003-08-21 | 2008-10-28 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine c-Kit inhibitors |
AU2004268950A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine-derivatives as c-kit inhibitors |
US7521448B2 (en) | 2003-08-21 | 2009-04-21 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-Kit inhibitors |
GB2423083B (en) | 2003-12-03 | 2007-07-11 | Cytopia Res Pty Ltd | Azole-based kinase inhibitors |
EP1711496A4 (en) | 2004-01-28 | 2009-02-11 | Smithkline Beecham Corp | THIAZOLE COMPOUNDS |
TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
US7566781B2 (en) | 2004-05-10 | 2009-07-28 | Banyu Pharmaceutical Co., Ltd. | Imidazopyridine compound |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
CN101048406B (zh) | 2004-08-31 | 2010-12-22 | 万有制药株式会社 | 新型取代的咪唑衍生物 |
US7709518B2 (en) | 2004-09-21 | 2010-05-04 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
US7419995B2 (en) * | 2004-12-01 | 2008-09-02 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library |
EP1832588A4 (en) | 2004-12-28 | 2009-09-02 | Takeda Pharmaceutical | IMIDAZOLE CONDENSE DERIVATIVE AND APPLICATIONS THEREOF |
EP1836188A1 (en) | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
AU2006218403A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
KR20080013886A (ko) | 2005-04-05 | 2008-02-13 | 파마코페이아, 인코포레이티드 | 면역억제용 퓨린 및 이미다조피리딘 유도체 |
FR2884821B1 (fr) * | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
EP1934213A1 (en) | 2005-09-30 | 2008-06-25 | Astra Zeneca AB | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
TW200812587A (en) | 2006-03-20 | 2008-03-16 | Synta Pharmaceuticals Corp | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
EP2004626A4 (en) | 2006-03-23 | 2010-10-27 | Synta Pharmaceuticals Corp | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS |
ITVA20060041A1 (it) | 2006-07-05 | 2008-01-06 | Dialectica Srl | Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington |
TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP1882475A1 (en) | 2006-07-26 | 2008-01-30 | Novartis AG | Method of treating disorders mediated by the fibroblast growth factor receptor |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
AR064491A1 (es) | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
JP5442449B2 (ja) * | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
RU2467008C2 (ru) | 2007-04-03 | 2012-11-20 | Эррэй Биофарма Инк. | СОЕДИНЕНИЯ ИМИДАЗО[1,2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ |
CN107021895A (zh) | 2007-06-12 | 2017-08-08 | 尔察祯有限公司 | 抗菌剂 |
EP2170882A1 (en) | 2007-06-26 | 2010-04-07 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
-
2007
- 2007-10-12 GB GBGB0720038.9A patent/GB0720038D0/en not_active Ceased
-
2008
- 2008-10-10 US US12/682,478 patent/US8071614B2/en active Active
- 2008-10-10 WO PCT/GB2008/003439 patent/WO2009047522A1/en active Application Filing
- 2008-10-10 EP EP08806575.0A patent/EP2203449B1/en active Active
- 2008-10-10 PT PT88065750T patent/PT2203449T/pt unknown
- 2008-10-10 CA CA2701868A patent/CA2701868C/en active Active
- 2008-10-10 ME MEP-2016-141A patent/ME02815B/me unknown
- 2008-10-10 PL PL08806575T patent/PL2203449T3/pl unknown
- 2008-10-10 SI SI200831645A patent/SI2203449T1/sl unknown
- 2008-10-10 JP JP2010528481A patent/JP5562858B2/ja active Active
- 2008-10-10 HU HUE08806575A patent/HUE028999T2/en unknown
- 2008-10-10 RS RS20160587A patent/RS55045B1/sr unknown
- 2008-10-10 ES ES08806575.0T patent/ES2585352T3/es active Active
- 2008-10-10 AU AU2008309342A patent/AU2008309342C1/en not_active Ceased
-
2010
- 2010-12-21 HK HK10111956.7A patent/HK1145496A1/zh not_active IP Right Cessation
-
2011
- 2011-10-18 US US13/275,752 patent/US8859582B2/en active Active
-
2016
- 2016-07-13 HR HRP20160852TT patent/HRP20160852T1/hr unknown
- 2016-07-25 CY CY20161100727T patent/CY1117820T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2701868C (en) | 2016-07-19 |
HK1145496A1 (zh) | 2011-04-21 |
US8071614B2 (en) | 2011-12-06 |
EP2203449B1 (en) | 2016-04-27 |
CA2701868A1 (en) | 2009-04-16 |
US20100286113A1 (en) | 2010-11-11 |
PL2203449T3 (pl) | 2017-03-31 |
RS55045B1 (sr) | 2016-12-30 |
JP2011500545A (ja) | 2011-01-06 |
SI2203449T1 (sl) | 2016-10-28 |
HUE028999T2 (en) | 2017-02-28 |
JP5562858B2 (ja) | 2014-07-30 |
ES2585352T3 (es) | 2016-10-05 |
CY1117820T1 (el) | 2017-05-17 |
PT2203449T (pt) | 2016-08-02 |
AU2008309342C1 (en) | 2014-08-28 |
EP2203449A1 (en) | 2010-07-07 |
AU2008309342A1 (en) | 2009-04-16 |
HRP20160852T1 (hr) | 2016-09-23 |
WO2009047522A1 (en) | 2009-04-16 |
US20120035152A1 (en) | 2012-02-09 |
US8859582B2 (en) | 2014-10-14 |
ME02815B (me) | 2018-01-20 |
AU2008309342B2 (en) | 2014-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0720038D0 (en) | New compounds | |
GB0720041D0 (en) | New Compounds | |
GB0704407D0 (en) | Compounds | |
GB0704394D0 (en) | Compounds | |
GB0722769D0 (en) | New compounds | |
GB0701273D0 (en) | New compounds | |
GB0705672D0 (en) | Compounds | |
GB0706173D0 (en) | Compounds | |
GB0706168D0 (en) | Compounds | |
GB0706165D0 (en) | Compounds | |
GB0706188D0 (en) | Compounds | |
HU0700395D0 (en) | New compounds | |
GB0706174D0 (en) | Compounds | |
GB0706187D0 (en) | Compounds | |
GB0706167D0 (en) | Compounds | |
GB0706189D0 (en) | Compounds | |
GB0706170D0 (en) | Compounds | |
GB0706190D0 (en) | Compounds | |
GB0706164D0 (en) | Compounds | |
GB0704939D0 (en) | Compounds | |
GB0703756D0 (en) | Compounds | |
GB0701985D0 (en) | Compounds | |
GB0720000D0 (en) | New compounds | |
GB0719998D0 (en) | New compounds | |
GB0701780D0 (en) | New compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |